A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 299 participants.

Also called NCT06326047

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 299 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06326047
  • jRCT jRCT2031230704
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Canada, India, Japan, South Africa, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06326047. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-18 (actual); primary completion 2025-09-19 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
NNC0519-0130
Intervention (Drug)
Placebo
Intervention (Drug)
Trizepatide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct06326047
Content hash
521c3228e7c596c1f1d08ada857bea55ba5b1c2eb7c95aa330bf1d50c603365c